CLOs on the Move

Karuna Therapeutics

www.karunatx.com

 
At Karuna, our purpose is to create and deliver transformative medicines for people living with psychiatric and neurological conditions. Through the cultivation of our deep expertise in neuroscience, and inventive thinking around drug discovery and development, we are advancing a pipeline of novel medicines with the goal of providing a meaningful difference in the lives of those affected by these conditions. Our culture is defined by our passion to serve those affected by mental illness. We are purpose-driven and intentional. We know impactful innovations don`t come easy, but are borne from passion and hard work. Together, we are working ...
  • Number of Employees: 250-1000
  • Annual Revenue: $1-10 Million
  • www.karunatx.com
  • 99 High Street Floor 26
    Boston, MA USA 02110
  • Phone: 857.449.2244

Executives

Name Title Contact Details

Similar Companies

Poxel

Poxel is a dynamic biopharmaceutical company that uses its extensive expertise in developing innovative drugs for metabolic diseases, with a focus on type 2 diabetes and non-alcoholic steatohepatitis (NASH). In its mid-to-late stage pipeline, the Company is currently advancing three drug candidates as well as earlier-stage opportunities. Imeglimin, Poxel`s first-in-class lead product, targets mitochondrial dysfunction. Together, with its partner Sumitomo Dainippon Pharma, Poxel is conducting the Phase 3 Trials of IMeglimin for Efficacy and Safety (TIMES) program for the treatment of type 2 diabetes in Japan. Poxel also established a partnership with Roivant Sciences for Imeglimin`s development and commercialization in countries outside of the partnership with Sumitomo Dainippon Pharma, including the U.S. and Europe. PXL770, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is in a Phase 2a proof-of-concept program for the treatment of NASH. PXL770 could also have the potential to treat additional metabolic diseases. PXL065 (deuterium-stabilized R-pioglitazone), a mitochondrial pyruvate carrier (MPC) inhibitor, is in Phase 1 clinical testing and being developed for the treatment of NASH. Poxel also has additional earlier-stage programs targeting metabolic, specialty and rare diseases. The Company intends to generate further growth through strategic partnerships and pipeline development. Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan.

NPS Pharmaceuticals

NPS Pharmaceuticals is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.

Lacerta Therapeutics

Clinical stage gene therapy company using a constellation of proprietary AAV vector technologies to develop novel treatments for central nervous system and lysosomal storage diseases

Scrippshealth

Scrippshealth is a Lajolla, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Vitro Naturals

Vitro Naturals is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.